Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 10/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264229 | 0.87 | ALDH1A1 (0.39) | ALDH1A1GAACASP7 | |
| SCHEMBL5265193 | 0.85 | PDE3B (0.39) | ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL5260022 | 0.82 | MAPT (0.45) | ALDH1A1GAASMN1; SMN2KCNH2 | |
| SCHEMBL5262125 | 0.81 | KMT2A (0.40) | ALDH1A1 | |
| SCHEMBL5260904 | 0.81 | HTR1A (0.39) | CDK9CCNT1ALDH1A1GAACASP7 | |
| SCHEMBL5262158 | 0.79 | KDM4E (0.41) | ALDH1A1GAACASP7SMN1; SMN2 | |
| SCHEMBL5264178 | 0.78 | KDM4E (0.50) | ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL5262896 | 0.78 | KDM4E (0.41) | ALDH1A1GAACASP7SMN1; SMN2 | |
| SCHEMBL5264644 | 0.78 | KMT2A (0.36) | ALDH1A1GAASMN1; SMN2KCNH2 | |
| SCHEMBL5259891 | 0.76 | GFER (0.35) | ALDH1A1GAASMN1; SMN2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-06-09 | — | — | US | claimed |
| EP-1644343-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |
| CN-1845908-A | 5-substituted quinazolinone derivatives | HOFFMANN LA ROCHE (CH) | 2006-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1B, ADRB2 | CDK9 2329/4885CCNT1 812/4885TLR9 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.